Results 241 to 250 of about 106,090 (294)

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway. [PDF]

Cureus
Felber R, New W, Riskin SI.
europepmc   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Effect of Angiotensin-Converting Enzyme Inhibitor on the Interdialytic Body Weight Gain of Patients on Maintenance Hemodialysis.

, 1997
Kim Mk, Yoon Td, Su Dd, Lee Jy, Kim Yk, Lee Hg, Kim Ty, Yong Seon Choi, Jingyuan Kong   +8 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1988
There is convincing evidence that ACE inhibitors, alone or in combination with a diuretic, effectively lower blood pressure in patients with all grades of essential or renovascular hypertension and that they are of particular benefit as adjunctive therapy in patients with congestive heart failure.
H H, Rotmensch, P H, Vlasses, R K, Ferguson   +2 more
  +7 more sources

[Angiotensin-converting enzyme inhibitors].

Recenti progressi in medicina, 1991
The introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension and heart failure is probably the most important advance in cardiovascular pharmacotherapy in the last few decades. Although the role of the renin-angiotensin system (RAS) in cardiovascular diseases had been investigated extensively for more than 70 yr,
Irene Gavras, Haralambos Gavras
openaire   +4 more sources

Angiotensin Converting Enzyme Inhibitors

American Journal of Hypertension, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
B L, Herlihy, J T, Herlihy
openaire   +4 more sources

Angiotensin-Converting Enzyme Inhibitor Angioedema

Advanced Emergency Nursing Journal, 2020
Angioedema from angiotensin-converting enzyme inhibitors (ACEIs) is a potential, emergent, and frightening problem that presents to the emergency department. This article focuses on angioedema caused by using ACEIs. The presentation, pathology, diagnostic testing, treatment, and patient education of angioedema are explored.
Josh, Bankston, David Thomas, House
openaire   +4 more sources

Angiotensin-converting enzyme inhibitors

Journal of the American Academy of Dermatology, 1994
Over many decades, the role of renin-angrotensin system in cardiovascular disorders has been redefined and expanded. Strongly interwoven with this process has been the development of pharmacologic probes that have helped to define this role.
  +7 more sources